fatty15
Chris Doyle is an experienced financial executive currently serving as Chief Financial Officer at both Seraphina Therapeutics and fatty15 since November 2022. Previously, Chris held the CFO position at Diggs Pet, where leadership was provided for the finance function of a rapidly growing pet products startup. Prior roles include Global Finance Director at Mars, managing financial planning for the Health & Wellness snacking platform, and various positions at Moelis & Company, including Investment Banking Associate and Summer Associate, where responsibilities involved M&A transaction processes and financial modeling. Chris's early career includes significant roles at J.P. Morgan in the Securitized Products Group. Academic credentials include an MBA from Yale School of Management and a BA in Economics from Williams College.
This person is not in any teams
This person is not in any offices
fatty15
Who are we? As a consortium of doctors, scientists, and innovators, we're dedicated to pioneering health at the cellular level. Fatty15 is the result of years of research and development — to isolate the good fat we need and put it back in our bodies to help protect against age-related breakdown. So from the bottom of our cardiovascular muscles (hearts), thank you. We couldn't be more excited to have you in the fatty15 family very soon.